Tevogen (TVGN) Income from Continuing Operations (2023 - 2026)
Tevogen Bio Holdings' (TVGN) quarterly Income from Continuing Operations came in at 5400920.0 in Q1 2026, up 47.97% YoY from 3649945.59 in Q1 2025, and up 77.03% on a QoQ basis from 23508396.0 in Q4 2025.
Tevogen (TVGN) Income from Continuing Operations (2023 - 2026) Analysis & Trends
Tevogen Bio Holdings (TVGN) has 4 years of Income from Continuing Operations data on file, last reported at 5400920.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 47.97% year-over-year to 5400920.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 40083283.0 (down 13.39% YoY) and the FY2025 annual result came in at 45038710.0, up 17.57% from the prior year.
- Income from Continuing Operations grew to 5400920.0 in Q1 2026, from 23508396.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 2184466.0 in Q2 2023 to a low of 29672510.0 in Q1 2024.
- A 4-year average of 8835024.0 and a median of 5729431.0 in 2025 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2024 — Income from Continuing Operations sank 1035.45% — and 2025, when it jumped 65.02%.
- Tracing TVGN's Income from Continuing Operations over 4 years: stood at 2326794.0 in 2023, then sank by 341.47% to 10272098.0 in 2024, then plunged by 128.86% to 23508396.0 in 2025, then soared by 77.03% to 5400920.0 in 2026.
- The last three Income from Continuing Operations figures came in at 5400920.0 (Q1 2026), 23508396.0 (Q4 2025), and 5729431.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Tevogen | 25.62 Mn | 25.62 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.40 Mn |
| Dec 31, 2025 | -23.51 Mn |
| Sep 30, 2025 | -5.73 Mn |
| Jun 30, 2025 | -5.44 Mn |
| Mar 31, 2025 | -10.38 Mn |
| Dec 31, 2024 | -10.27 Mn |
| Sep 30, 2024 | -6.10 Mn |
| Jun 30, 2024 | -8.60 Mn |
| Mar 31, 2024 | -29.67 Mn |
| Dec 31, 2023 | -2.33 Mn |
| Sep 30, 2023 | -2.62 Mn |
| Jun 30, 2023 | -2.18 Mn |
| Mar 31, 2023 | -2.61 Mn |